These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 27106404)

  • 1. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
    Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
    Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
    Boursier C; Zaragori T; Bros M; Bordonne M; Melki S; Taillandier L; Blonski M; Roch V; Marie PY; Karcher G; Imbert L; Verger A
    Eur Radiol; 2023 Oct; 33(10):7089-7098. PubMed ID: 37148355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up.
    Severi S; Grassi I; Bongiovanni A; Nicolini S; Marini I; Arpa D; Ranallo N; Azzali I; Di Iorio V; Sarnelli A; Manuela M; Amadori E; Fabbri L; Bartolini D; Tosatto L; Di Meco F; Gurrieri L; Riva N; Calabro L; Matteucci F; Paganelli G; Sansovini M
    J Nucl Med; 2024 Sep; 65(9):1409-1415. PubMed ID: 39142827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma.
    Müther M; Roll W; Brokinkel B; Zinnhardt B; Sporns PB; Seifert R; Schäfers M; Weckesser M; Stegger L; Stummer W; Rahbar K
    Nuklearmedizin; 2020 Sep; 59(5):348-355. PubMed ID: 32691404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma.
    Kurz SC; Zan E; Cordova C; Troxel AB; Barbaro M; Silverman JS; Snuderl M; Zagzag D; Kondziolka D; Golfinos JG; Chi AS; Sulman EP
    Clin Cancer Res; 2024 Feb; 30(4):680-686. PubMed ID: 38048045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma.
    Hänscheid H; Sweeney RA; Flentje M; Buck AK; Löhr M; Samnick S; Kreissl M; Verburg FA
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1284-8. PubMed ID: 22526964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.
    Bartolomei M; Bodei L; De Cicco C; Grana CM; Cremonesi M; Botteri E; Baio SM; Aricò D; Sansovini M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1407-16. PubMed ID: 19319527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung Metastases of Intracranial Atypical Meningioma Diagnosed on Posttherapeutic Imaging After 177Lu-DOTATATE Therapy.
    Backhaus P; Huss S; Kösek V; Weckesser M; Rahbar K
    Clin Nucl Med; 2018 Jun; 43(6):e184-e185. PubMed ID: 29688946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.
    Graf J; Pape UF; Jann H; Denecke T; Arsenic R; Brenner W; Pavel M; Prasad V
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):881-894. PubMed ID: 31414209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
    Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
    Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will
    Braat AJAT; Snijders TJ; Seute T; Vonken EPA
    Cardiovasc Intervent Radiol; 2019 Nov; 42(11):1649-1652. PubMed ID: 31187231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin Receptor Theranostics for Refractory Meningiomas.
    Salgues B; Graillon T; Horowitz T; Chinot O; Padovani L; Taïeb D; Guedj E
    Curr Oncol; 2022 Aug; 29(8):5550-5565. PubMed ID: 36005176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET.
    Milker-Zabel S; Zabel-du Bois A; Henze M; Huber P; Schulz-Ertner D; Hoess A; Haberkorn U; Debus J
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):222-7. PubMed ID: 16488553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRRT with Lu-177 DOTATATE in Treatment-Refractory Progressive Meningioma: Initial Experience from a Tertiary-Care Neuro-Oncology Center.
    Puranik AD; Dev ID; Rangarajan V; Kulkarni S; Shetty N; Gala K; Sahu A; Bhattacharya K; Dasgupta A; Chatterjee A; Gupta T; Sridhar E; Sahay A; Shetty P; Singh V; Moiyadi A; Menon N; Purandare NC; Agrawal A; Shah S; Choudhury S; Ghosh S; Jha AK
    Neurol India; 2024 Mar; 72(2):278-284. PubMed ID: 38691470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.
    Eigler C; McDougall L; Bauman A; Bernhardt P; Hentschel M; Blackham KA; Nicolas G; Fani M; Wild D; Cordier D
    J Nucl Med; 2024 Apr; 65(4):573-579. PubMed ID: 38423782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review.
    Boursier C; Zaragori T; Imbert L; Verger A
    Q J Nucl Med Mol Imaging; 2024 Sep; 68(3):217-225. PubMed ID: 39026463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of radiolabelled somatostatin analogues (
    Medina-Ornelas SS; García-Pérez FO
    Rev Esp Med Nucl Imagen Mol; 2017; 36(3):166-174. PubMed ID: 27890514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.
    Henze M; Dimitrakopoulou-Strauss A; Milker-Zabel S; Schuhmacher J; Strauss LG; Doll J; Mäcke HR; Eisenhut M; Debus J; Haberkorn U
    J Nucl Med; 2005 May; 46(5):763-9. PubMed ID: 15872348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.